Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Bobin

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Cancers|October 23, 2021
Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review ArticleArthur Bobin, Cécile Gruchet, Stéphanie Guidez, et al.
Journal of Clinical Medicine|November 7, 2020
Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma PatientsHélène Gardeney, Arthur Bobin, Cécile Gruchet, et al.
Leukemia & Lymphoma|October 21, 2021
Smoldering multiple myeloma: biology, clinical manifestations and managementLaly Nsiala, Arthur Bobin, Anthony Levy, et al.
Cancer Medicine|March 9, 2019
Long-term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98-LEDGF rearrangementMaria Pilar Gallego Hernanz, José Miguel Torregrosa Diaz, Nathalie Sorel, et al.
Cancers|October 14, 2020
Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020Arthur Bobin, Evelyne Liuu, Niels Moya, et al.
Blood Advances|August 27, 2025
Risk of synchronous and second primary malignancies in multiple myeloma transplant-ineligible treated with lenalidomideThomas Systchenko, Ialy Nsiala, Arthur Bobin, et al.
Expert Opinion on Drug Delivery|April 13, 2026
Review of the first on-body injector (obi) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myelomaEnrique M Ocio, Gurdeep Parmar, María-Victoria Mateos, et al.
British Journal of Haematology|May 7, 2026
A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II studyArthur Bobin, Margaret Macro, Cyrille Touzeau, et al.
Blood Cancer Journal|October 21, 2025
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort studyThomas Chalopin, Elise Cellerin, Hélène Demarquette, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2025
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort StudyAlexis Talbot, Cyrille Hulin, Aurore Perrot, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Cancers|October 23, 2021
Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review ArticleArthur Bobin, Cécile Gruchet, Stéphanie Guidez, et al.
Journal of Clinical Medicine|November 7, 2020
Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma PatientsHélène Gardeney, Arthur Bobin, Cécile Gruchet, et al.
Leukemia & Lymphoma|October 21, 2021
Smoldering multiple myeloma: biology, clinical manifestations and managementLaly Nsiala, Arthur Bobin, Anthony Levy, et al.
Cancer Medicine|March 9, 2019
Long-term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98-LEDGF rearrangementMaria Pilar Gallego Hernanz, José Miguel Torregrosa Diaz, Nathalie Sorel, et al.
Cancers|October 14, 2020
Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020Arthur Bobin, Evelyne Liuu, Niels Moya, et al.
Blood Advances|August 27, 2025
Risk of synchronous and second primary malignancies in multiple myeloma transplant-ineligible treated with lenalidomideThomas Systchenko, Ialy Nsiala, Arthur Bobin, et al.
Expert Opinion on Drug Delivery|April 13, 2026
Review of the first on-body injector (obi) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myelomaEnrique M Ocio, Gurdeep Parmar, María-Victoria Mateos, et al.
British Journal of Haematology|May 7, 2026
A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II studyArthur Bobin, Margaret Macro, Cyrille Touzeau, et al.
Blood Cancer Journal|October 21, 2025
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort studyThomas Chalopin, Elise Cellerin, Hélène Demarquette, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2025
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort StudyAlexis Talbot, Cyrille Hulin, Aurore Perrot, et al.
Pageof 5